Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CAPRBullishCorporate Developmentsnews

High materiality8/10

Capricor's Deramiocel BLA advances to FDA advisory with HOPE-3 success

Jun 26, 2026, 10:07 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive HOPE-3 data and imminent advisory/PDUFA dates create a meaningful near-term upside risk-reward for CAPR, typical of biotech regulatory catalysts.

AI summary

What happened, with direct paths to the underlying reporting

Capricor Therapeutics announced that the FDA’s CTGTAC will review Deramiocel (CAP-1002) for Duchenne muscular dystrophy at a July 29, 2026 advisory meeting, with the BLA on track for an August 22, 2026 PDUFA date. Positive HOPE-3 results support a potential first-in-class approval path, reinforced by RMAT, orphan, and other designations that may streamline regulatory review.

FDA CTGTAC advisory meeting for Deramiocel on July 29, 2026; live stream planned.
HOPE-3 success: primary endpoint PUL v2.0 and key cardiac endpoint LVEF achieved.
RMAT, Orphan Drug, ATMP, and Rare Pediatric Disease designations may enable faster review.
Deramiocel (CAP-1002) is allogeneic CDCs with potential first-in-class DMD therapy.
PDUFA target date set for August 22, 2026; near-term regulatory catalyst.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Capricor's Deramiocel BLA advances to FDA advisory with HOPE-3 success

Capricor CAPR: PDUFA extended; HOPE-3 data strengthen upper-limb indication

Capricor Gains on Regulator Willingness to Review Duchenne Drug Data

Capricor Faces FDA Advisory Verdict on Deramiocel Ahead of PDUFA Date

Capricor faces legal probe and FDA data questions after Reuters report